Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 326INDUSTRY 47NIH 23NETWORK 11OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Lenalidomide × Clear all
NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Completed
60 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04065789 2022-01-27

KyDaR

Tel-Aviv Sourasky Medical Center

Phase 2 Completed
41 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡